MaxCyte signs cell platform deal with CRISPR and Casebia – DIGITALLOOK
DIGITALLOOKMaxCyte signs cell platform deal with CRISPR and CasebiaDIGITALLOOKCRISPR Therapeutics, a Nasdaq-listed biopharmaceutical company focussed on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a join… Continue reading
